Fenazopiridina

Quick links

Choose a section

Quick links to important sections

Advertisements

Fenazopiridina

Advertisements
Advertisements

Method of action: Analgesic, Analgetic

Advertisements

Overview of Fenazopiridina

Property Description
Active ingredient Phenazopyridine hydrochloride
Form Oral tablets or capsules
Pharmacological class Urinary analgesic (Symptomatic relief)
General use Alleviating lower urinary tract discomfort
Origin Synthetic azo dye

Defining Fenazopiridina: Class and Chemical Identity

Phenazopyridine (Fenazopiridina) is a synthetic organic compound classified as a urinary analgesic. This chemical entity, structurally identified as an azo dye, provides focused pain relief specifically within the lower urinary tract environment. The active ingredient is Phenazopyridine hydrochloride, which is administered as a single-ingredient product, confirming its function is purely dedicated to symptom management, separate from any anti-infective properties. Phenazopyridine is a urinary tract analgesic used to treat pain, burning, and urgency associated with urinary irritation. This analgesic function is clinically recognized for providing immediate relief in discomfort scenarios where tissue irritation is a primary concern.

Composition, Form, and General Therapeutic Role

The medicine is manufactured for oral administration, typically as tablets or capsules. The core function of Phenazopyridine is to offer symptomatic relief from irritation affecting the lower urinary tract mucosa. Its action helps to alleviate common and distressing symptoms, including dysuria (painful urination), a heightened urinary urgency, and increased frequency of urination. Its widespread use in these scenarios is characterized by its unique property of exerting a local anesthetic action on the mucosa. For instance, the drug is routinely used as an adjunct when a patient experiences acute discomfort during a lower urinary tract irritation episode.

High-Level Action and Distinctive Characteristic

Phenazopyridine works by exerting a localized analgesic effect, providing a topical soothing action directly on the lining of the urinary tract. After ingestion, the substance is rapidly excreted by the kidneys, allowing it to contact and numb the irritated tissue. This pattern of localized analgesic action is the drug’s primary differentiating factor, as its therapeutic effect is concentrated on the site of irritation. Due to its chemical structure as an azo dye, a highly predictable and expected consequence of its use—a distinctive feature of the compound—is a change in the color of the urine to a pronounced red-orange hue.

Regulatory References

  1. MedlinePlus Drug Information: Phenazopyridine
  2. Phenazopyridine FDA Drug Label
Advertisements

What side effects are possible with Fenazopiridina?

Possible Side Effects and Safety Information

The safety profile of Fenazopiridina (Phenazopyridine) is based strictly on regulatory documents and is defined by its chemical properties and excretion through the kidneys. The officially documented adverse reactions are categorized by the body system affected.

Documented Adverse Reactions

Gastrointestinal disturbances, such as nausea, vomiting, and diarrhea, are reported as occasional reactions. Reactions affecting the skin and immunity (Dermatologic/Hypersensitivity) include rash, pruritus (itching), skin discoloration, and the potential for severe reactions such as anaphylactoid-like reactions and hypersensitivity hepatitis.

Serious Adverse Reactions and Organ Systems

Serious adverse reactions primarily affect the blood and organs. These include methemoglobinemia, hemolytic anemia, and sulfhemoglobinemia, which are reported as occurring usually at overdosage levels. Other serious events are renal toxicity and hepatic toxicity, alongside the formation of renal calculi (kidney stones). Effects on the nervous system may include headache and visual disturbances.

Safety Constraints and Considerations

The medicine is contraindicated in patients with renal insufficiency or severe hepatitis due to the risk of systemic accumulation, which can lead to toxic reactions. Caution is also advised for patients with G-6-PD deficiency due to the potential for hemolytic anemia. An expected effect is the pronounced reddish-orange discoloration of the urine. Importantly, the drug’s dye properties can interfere with certain laboratory tests that rely on color-based analysis, potentially leading to inaccurate results for tests such as glucose or bilirubin in the urine.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Phenazopyridine (Fenazopiridina) is defined by the risk of severe systemic and hematological toxicities, which require immediate medical attention.

Documented Overdose Manifestations

Overdosage or toxic reactions may lead to elevated serum levels and manifest as Methemoglobinemia, particularly following a massive, acute overdose. A chronic overdosage may result in oxidative Heinz body hemolytic anemia, with the presence of “bite cells” (degmacytes) documented in laboratory findings. Systemic effects include renal toxicity, occasional renal failure, and hepatic impairment.

Factors and Emergency Response

  • Risk Factors: Toxic reactions are often associated with exceeding the recommended dose or administering the drug to patients with pre-existing impaired renal function. This risk is noted for elderly patients due to common declines in kidney function. Patients with red blood cell G-6-PD deficiency are predisposed to hemolysis.
  • Emergency Action: Regulatory documents mandate that in case of overdose, one must get medical help or contact a Poison Control Center immediately. If accumulation is suspected, signaled by a yellowish color of the skin or sclerae, the drug must be immediately discontinued.

Management and Intervention

The treatment for overdose is defined as symptomatic and supportive. For Methemoglobinemia, the official prescribing information describes specific interventions involving the administration of Methylene blue (intravenously) or Ascorbic acid (orally).

Advertisements

Therapeutic Uses of Fenazopiridina

Quick Facts

  • Relief of Discomfort: Assists in the relief of pain, burning, and irritation within the urinary tract.
  • Addressing Symptoms: Helps reduce the feeling of urgency and frequency of urination.
  • Symptomatic Use: Indicated for relief when these symptoms arise from irritation of the lower urinary tract lining.

Fenazopiridina (known as Phenazopyridine in the US) is a medication utilized for the short-term, symptomatic relief of discomfort related to the lower urinary tract. It is indicated to help lessen the experience of uncomfortable symptoms, including pain, a burning sensation, and increased frequency or urgency of urination. These symptoms typically arise from the irritation of the urinary tract's mucosal lining.

This irritation may be associated with various conditions or procedures, such as infection, injury, surgical intervention, or the placement of medical devices like catheters. The primary role of the medication is to provide localized relief of these uncomfortable sensations.

It is important to understand that Fenazopiridina offers only symptomatic relief and is not a substitute for definitive treatment of the underlying cause, such as an antimicrobial for an infection. The medication is compatible with, and may be administered alongside, antibiotic therapy to help manage pain and discomfort until the primary treatment takes effect. The use of this drug for symptom management should not postpone diagnosis and appropriate treatment of the causative condition.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fenazopiridina — official regulatory information

The use of Fenazopiridina is strictly determined by population eligibility rules outlined in official regulatory documents, focusing on the patient’s ability to excrete the drug and specific health risks.


Absolute Contraindications

The medicine must not be used by individuals diagnosed with renal insufficiency or severe liver disease/severe hepatitis, as impaired organ function can prevent proper drug elimination, leading to accumulation and toxicity. Use is also contraindicated in patients with a history of hypersensitivity to the drug or its ingredients, and in cases of pyelonephritis of pregnancy.


Age- and Condition-Based Restrictions

The drug is available for use in adults and generally in children 12 years and older. However, safety and efficacy are not established in children under 12 years of age. Older adult patients require cautious use, as age-related decline in renal function increases the risk of accumulation. Patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency are advised to use the drug cautiously due to the potential for oxidative hemolysis.


Pregnancy and Lactation Status

Fenazopiridina is classified as Pregnancy Category B; its use is permitted only if the benefit clearly outweighs the risk due to a lack of adequate human studies. During lactation, caution is advised as it is not known whether the drug is excreted in human milk. Therapy must be discontinued immediately if a yellowish tinge appears on the skin or eyes, as this is an official indication of drug accumulation.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Fenazopiridina interaction patterns centers on managing the risk of drug accumulation and avoiding additive toxic effects. No specific drug-drug combination is formally listed as contraindicated in the primary labeling, and systematic studies of general drug-drug interactions have not been reported.

Interaction-Related Restrictions

The drug is formally contraindicated in patients with renal insufficiency or severe liver disease/hepatitis. This restriction exists because impaired elimination capacity can lead to the accumulation of the compound and subsequent toxicity, particularly in patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency.

Co-administration with Methemoglobinemia-Associated Agents carries an additive toxic potential, increasing the risk of methemoglobinemia. Furthermore, co-administration with Trimethoprim and Sulfamethoxazole is officially documented to alter the plasma concentrations of all three compounds, resulting in a 60% increase in Phenazopyridine levels.

For use with any antibacterial agent, there is a mandated time-limited rule that must not exceed 2 days of concurrent administration.

Diagnostic Interference

Due to the drug's properties as an azo dye, it causes procedural interference with diagnostic laboratory tests. This results in altered or false test values for urinalysis that rely on colorimetric, photometric, or fluorometric methods, affecting results for glucose, ketones, and bilirubin. No known direct interactions are documented with food, alcohol, or herbal products.

Advertisements

Mechanism of Action

How Phenazopyridine Works

Localized Analgesic Action in the Urinary Tract

Phenazopyridine is rapidly excreted into the urine, where it achieves high concentration and functions as a topical sensory modulator upon direct contact with the mucosa (lining) of the lower urinary tract, specifically the bladder and urethra. This pharmacodynamic action involves the nonspecific desensitization of local sensory nerve endings within the peripheral afferent pathways. This localized sensory dampening results in a reduction in afferent nerve excitability.


Modulation of Peripheral Afferent Neural Transmission

The drug's activity is focused on modulating peripheral sensory nerve function by physically interfering with the transmission of neural signals originating from the urinary tissue. This mechanism operates by limiting the excitability of the nerve fibers responsible for relaying somatic sensations. This modulation of peripheral afferent signaling may consequentially limit unregulated neural activity in the bladder wall and affect smooth muscle activity at the system level. The mechanism remains localized and non-systemic, relying on the drug's excretion pattern.

Advertisements

Dosage and Administration Information

How to Use Fenazopiridina: Official Administration Guidelines

Fenazopiridina (phenazopyridine hydrochloride) is administered exclusively by the oral route as a fixed-schedule medication for symptomatic relief. The guidelines establish precise rules regarding dosage, timing, and duration that structure the use of the medicine, ensuring its role as a short-term aid.

Standard Dosing and Administration

The most common standard adult dosing regimen is 200 mg taken three times daily (TID). This is the same dosage regimen typically applied to pediatric patients 12 years of age and older. The daily intake should generally not exceed 600 mg. The medication must be taken with or immediately after a meal or snack and swallowed with a full glass of water. This requirement is a standardized instruction intended to facilitate proper ingestion.

Administration Constraint Official Rule
Route of Administration Oral (Tablet or Capsule)
Standard Dosing 200 mg, three times daily (TID)
Timing Relative to Food Must be taken with or after meals

Treatment Duration and Specific Populations

Phenazopyridine is intended for short-term use only. When administered alongside an antibacterial agent for urinary tract infection, the duration of use must not exceed 2 days. The treatment should be discontinued immediately once the lower urinary tract symptoms are controlled, establishing its function as a temporary intervention. The drug is contraindicated in patients with renal insufficiency, and caution is required for older adults due to age-related decline in renal function. A predictable consequence of the drug's use is a reddish-orange discoloration of the urine due to its chemical nature as an azo dye.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fenazopiridina

Evidence for Symptomatic Relief of Lower Urinary Tract Irritation

Research examining Fenazopiridina (Phenazopyridine) was evaluated in short-term Randomized Controlled Trials (RCTs) and is supported by reviews of historical clinical data. These trials were typically used in research exploring how symptoms change over time in adult women evaluated in contexts involving pain, burning, and discomfort outcomes related to physical discomfort associated with irritation in the lower urinary tract. Studies explored changes in patient-reported outcomes describing perceived discomfort, often using standardized scales to measure the intensity of pain and burning upon urination.

Studies reported how symptoms evolved in the observed populations over very short follow-up durations, often within 24 hours of administration. Findings describe patterns observed in the studies related to changes in key symptoms, including urgency and frequency. Research involving this medicine is documented in regulatory reviews of short-term symptom management.

Evidence for Use in Urological Procedures

A separate line of research studies explored the use of this medication in contexts involving discomfort in patients undergoing specific urological or diagnostic procedures. This research was evaluated in smaller, focused RCTs and prospective studies. The studies examined outcomes related to systemic or functional imbalance, including the measurement of post-procedural voiding function and changes in patient-reported pain scores in the immediate post-procedure period.

Evidence quality varies across studies in this area, and sample sizes were modest in many trials. Data are still emerging for the use of this medicine in a broad range of surgical recovery scenarios, and results apply only to the populations studied during the immediate, acute phase following those procedures.

Research Gaps and Areas of Uncertainty

The evidence highlights what is known — and what is still uncertain — about Fenazopiridina. Long-term effects are not fully established, and comparative evidence is lacking for its use over extended periods. Data for certain groups remain insufficient, including specific trials for children or patients with significant underlying comorbid conditions. Overall, certainty remains low for effects beyond the immediate, acute symptomatic changes observed in the originally studied populations.

Key Studies & References

  1. Label: PHENAZOPYRIDINE HYDROCHLORIDE tablet - DailyMed (NIH)
  2. Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI) | ClinicalTrials.gov
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fenazopiridina (FAQ)


Q: Can Fenazopiridina change the color of my contact lenses?

A: Regulatory documents state that Fenazopiridina may cause the discoloration or staining of soft contact lenses. Official information notes that the stain caused by the drug may be difficult or impossible to remove.


Q: Is it true that Fenazopiridina can stain toilets?

A: As an azo dye, Fenazopiridina turns urine a pronounced orange-to-red color. Official patient information notes that this may stain fabric and body fluids, and the highly colored urine carries the potential to stain any surface it contacts, including porcelain.


Q: How long does it take for Fenazopiridina to start working for pain?

A: Clinical reviews suggest that the medicine’s analgesic effect typically begins quickly, often within a few hours of the first dose. Clinical studies have examined symptom changes within short follow-up periods, with some reports noting the onset of effect within 24 hours of starting treatment.


Q: What are the general expectations for pain relief after starting Fenazopiridina?

A: Fenazopiridina is indicated for the focused symptomatic relief of irritation in the lower urinary tract. Its localized analgesic action is intended to help relieve specific discomforts like pain, burning, urgency, and frequency.


Q: Does Fenazopiridina cause stomach upset or nausea?

A: Adverse reaction listings include occasional gastrointestinal disturbances, such as nausea. Official patient instructions specify that the medication should be taken with or immediately following food or a snack, which is a method intended to help reduce the possibility of stomach upset.


Q: Does Fenazopiridina interfere with the results of lab tests?

A: Yes, Fenazopiridina can interfere with certain lab tests because it is an azo dye. It may cause false or altered results in urine tests that rely on color changes for analysis, which affects tests for substances like glucose, ketones, and bilirubin.


Q: Can I take Fenazopiridina with cranberry supplements?

A: Systematic interaction studies with herbal or dietary supplements, including cranberry, are not widely reported. The official label notes that no significant interactions have been reported in the medical literature.


Q: Does Fenazopiridina have any known interactions with alcohol?

A: Official drug labels do not document direct interactions between Fenazopiridina and alcohol. Patients are generally encouraged to discuss the use of any medication in conjunction with alcohol with a healthcare professional.


Q: Can Fenazopiridina be used for pain after a medical procedure like a cystoscopy?

A: Fenazopiridina is indicated for the symptomatic relief of irritation of the lower urinary tract mucosa caused by various sources, including endoscopic procedures. It is officially used to help manage the discomfort that may arise following such urological procedures.


Q: Is Fenazopiridina considered a strong painkiller?

A: Fenazopiridina is classified as a urinary analgesic that provides a specific, localized analgesic effect in the urinary tract. Official information notes that this localized action may reduce or eliminate the need for systemic pain relievers.


Q: Can Fenazopiridina be taken on an empty stomach?

A: Official patient instructions specify that the medication should be taken with or immediately following food or a snack. This requirement relates to reducing the possibility of stomach upset.


Q: Do I need a prescription to get Fenazopiridina?

A: Fenazopiridina is available in two forms: over-the-counter (OTC) in lower strengths and by prescription in higher strengths. Availability varies based on the country and the specific product’s dose.


Q: What should I do if I forget to take a dose of Fenazopiridina?

A: Regulatory consumer information addresses missed doses by suggesting that the missed dose be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the information states to skip the missed dose and continue with the regular schedule without taking a double dose.


Q: Is Fenazopiridina safe to use for kidney pain?

A: Fenazopiridina is indicated for irritation of the lower urinary tract mucosa (bladder and urethra), not the kidneys. Furthermore, the drug is officially contraindicated (should not be used) in patients with renal insufficiency, which is severe kidney disease, due to the risk of drug accumulation.


Q: Can men take Fenazopiridina?

A: Yes, the medication is indicated for the symptomatic relief of lower urinary tract discomfort in all adult patients regardless of gender. The dosage regimen is the same for men and women.


Q: How long can I safely use Fenazopiridina for bladder discomfort?

A: The medicine is indicated for use as a temporary measure only. When it is administered alongside an antibacterial agent for a urinary tract infection, treatment is officially stated to not exceed 2 days. The regulatory direction states that the medication is to be discontinued once the symptoms are controlled.


Q: Does Fenazopiridina interact with birth control pills?

A: Systematic drug interaction studies have not been widely reported, and the primary regulatory labels state no significant interactions have been reported in the medical literature to date. Specific interactions with hormonal contraceptives, such as birth control pills, are not detailed in the official label.


Q: Is Fenazopiridina available in generic form?

A: Yes, the active ingredient, Phenazopyridine hydrochloride, is widely available in lower-cost generic versions. These generic products are available in addition to various brand-name products.


Q: Are there any dietary restrictions while taking Fenazopiridina?

A: The official label does not document any specific dietary restrictions due to direct drug-food interactions. However, the medicine is required to be taken with food to help reduce the possibility of stomach upset.


Q: Does Fenazopiridina affect fertility?

A: The medicine’s regulatory profile notes that reproduction studies conducted in rats showed no evidence of impaired fertility. Official information confirms that available data are currently insufficient to evaluate the long-term effects in humans.


Q: Are the orange/red stains from Fenazopiridina permanent?

A: The deep discoloration of the urine is an expected effect and will typically go away after the medication is stopped. However, the drug may stain soft contact lenses, and in those cases, the staining may not be possible to remove.


Q: Are there any documented cases of Fenazopiridina causing blood disorders?

A: Serious blood disorders, including methemoglobinemia and hemolytic anemia, have been reported in the official safety profile. These serious adverse reactions typically occur at levels exceeding the prescribed dose (overdosage levels).


Q: Can I take over-the-counter cold medicine while using Fenazopiridina?

A: Systematic drug interaction studies are not widely reported. Official information states that no significant interactions have been reported in the medical literature to date, but advises using caution when taking any other medicines, including over-the-counter products.


Q: Does Fenazopiridina affect sleep patterns?

A: Adverse reactions listed on the official label include specific nervous system effects such as headache. However, effects specifically on sleep patterns are not directly documented in the official safety profile.


Q: Is there a maximum number of days Fenazopiridina can be used?

A: When Fenazopiridina is used with an antibacterial agent for a urinary tract infection, official guidelines state that administration should not exceed 2 days. The medicine is indicated for short-term use and is to be discontinued when symptoms are controlled.


Q: What is the difference between the over-the-counter and prescription forms of Fenazopiridina?

A: The main difference between the forms is the strength of the dose available. Over-the-counter forms are typically marketed in lower strengths (e.g., 95 mg or 97.5 mg), while prescription forms are available in higher strengths (e.g., 100 mg or 200 mg).

Advertisements

How should Fenazopiridina be stored and disposed of?

How to Store and Dispose of Phenazopyridine Hydrochloride

To ensure the stability and safety of this medication, store Phenazopyridine Hydrochloride (Fenazopiridina) tablets at Controlled Room Temperature, which is 25 C (77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The product must be kept in the container it came in, tightly closed, and stored away from excess heat and moisture. When dispensed, the tablets should be in a tight, light-resistant container with a child-resistant closure.

Child Safety and Disposal

It is essential to keep this medication, and all drugs, out of the reach and sight of children. Always lock safety caps and store the medication in a secure, high location. Specific disposal instructions for unused or expired doses are generally based on local guidelines. If an overdose is suspected, immediately seek professional assistance or contact a poison control center.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fenazopiridina found in:

A-Z Index: